{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:54:49Z","timestamp":1790394889081,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jchromb.2023.123918","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T22:29:25Z","timestamp":1699309765000},"page":"123918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Validated extended multiplexed LC-MS\/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs"],"prefix":"10.1016","volume":"1231","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4907-4021","authenticated-orcid":false,"given":"Paul D.","family":"Kruithof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvo M.","family":"de Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith L.","family":"Gulikers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo M.L.","family":"Stolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Croes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.J.M.","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123918_b0005","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120858","article-title":"Personalized therapy for lung cancer: striking a moving target","volume":"3","author":"Pakkala","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jchromb.2023.123918_b0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jchromb.2023.123918_b0015","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of codebreak 100","volume":"41","author":"Dy","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2023.123918_b0020","unstructured":"T.S. Bekaii-Saab, R. Yaeger, A.I. Spira, M.S. Pelster, J.K. Sabari, N. Hafez, M. Barve, K. Velastegui, X. Yan, A. Shetty, H. Der-Torossian, S. Pant, Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation, J. Clin. Oncol. doi: 10.1200\/jco.23.00434(2023) Jco2300434."},{"key":"10.1016\/j.jchromb.2023.123918_b0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2023.123918_b0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2023.123918_b0035","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2023.123918_b0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2023.123918_b0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1039\/D1AN01928G","article-title":"Development and validation of a robust and sensitive HPLC-MS\/MS method for the quantitation of MRTX849 in plasma and its application in pharmacokinetics","volume":"147","author":"Du","year":"2022","journal-title":"Analyst"},{"key":"10.1016\/j.jchromb.2023.123918_b0050","doi-asserted-by":"crossref","first-page":"e5043","DOI":"10.1002\/bmc.5043","article-title":"Validated HPLC-MS\/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice","volume":"35","author":"Madhyastha","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2023.123918_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122718","article-title":"Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry","volume":"1174","author":"Retmana","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2023.123918_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115612","article-title":"Validated LC-MS\/MS method for simultaneous quantification of KRAS(G12C) inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study","volume":"235","author":"Retmana","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123918_b0065","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4155\/bio-2022-0173","article-title":"Validation of an LC-MS\/MS method for the determination of sotorasib, a KRAS(G12C) inhibitor, in human plasma","volume":"14","author":"Wong","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2023.123918_b0070","unstructured":"J.L. Gulikers, A.J. van Veelen, E.M.J. Sinkiewicz, Y.M. de Beer, M. Slikkerveer, L.M.L. Stolk, V.C.G. Tjan-Heijnen, L.E.L. Hendriks, S. Croes, R. van Geel, Development and validation of an HPLC-MS\/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma, Biomed. Chromatogr. DOI 10.1002\/bmc.5628(2023) e5628."},{"key":"10.1016\/j.jchromb.2023.123918_b0075","doi-asserted-by":"crossref","first-page":"e5224","DOI":"10.1002\/bmc.5224","article-title":"Development and validation of an HPLC-MS\/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run","volume":"35","author":"van Veelen","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2023.123918_b0080","doi-asserted-by":"crossref","first-page":"e4771","DOI":"10.1002\/bmc.4771","article-title":"Validation of an analytical method using HPLC-MS\/MS to quantify osimertinib in human plasma and supplementary stability results","volume":"34","author":"van Veelen","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2023.123918_b0085","unstructured":"European Medicines Agency, ICH M10 on bioanalytical method validation - Scientific guideline, 2022."},{"key":"10.1016\/j.jchromb.2023.123918_b0090","unstructured":"European Medicines Agency, Guideline on bioanalytical validation, in: CHMP (Ed.), 2012."},{"key":"10.1016\/j.jchromb.2023.123918_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2021.12.028","article-title":"Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry","volume":"527","author":"Xiong","year":"2022","journal-title":"Clin. Chim. Acta"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:12:33Z","timestamp":1761606753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223003288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"alternative-id":["S1570023223003288"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123918","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validated extended multiplexed LC-MS\/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123918"}}